Expansion Opportunity QPS is actively expanding its physical footprint with new offices and lab facilities in Springfield, Massachusetts and Newark, New Jersey, signaling increased demand and potential needs for additional CRO capabilities, site management, and regional clinical operations support.

Clinical Excellence As a GLP/GCP-compliant full-service CRO with strengths in neuropharmacology, DMPK, toxicology, bioanalysis and translational medicine, QPS may require expanded analytical instrumentation, validated bioanalytical workflows, and scalable lab automation to support growing clinical trial throughput.

Tech Integration QPS partners with multiple tech providers and has leveraged platforms like NetSuite, Azure and analytics tools; this creates opportunities to offer advanced data management, cloud security, and AI-enabled trial optimization, including integration with existing tech stack.

Strategic Partnerships Recent collaborations, including a strategic AI partnership with Ryght, indicate openness to technology-driven process improvements; potential sales angles include AI-powered trial design, patient recruitment optimization, and real-time analytics for global studies.

Talent and Capacity Significant headcount growth in 2024–2025 and the launch of cell therapy capabilities suggest ongoing capacity expansion and specialized service needs; potential opportunities in CRO staffing solutions, facilities management, and specialized manufacturing support for cell therapy and leukopak products.